AmerisourceBergen Drug vs ACASA Senior Care

AmerisourceBergen Drug’s 2,361 total units — nearly all franchised — create a total addressable market that dwarfs ACASA Senior Care’s 8-unit footprint by two orders of magnitude. Even without a published AUV, the sheer breadth of locations turns a software sale into a volume play: a single point-of-sale or scheduling rollout across 2,200+ independently operated sites generates license and implementation revenue that no eight-unit chain can match. ACASA’s $6.9M AUV signals a potentially larger wallet per location, but that budget advantage caps out quickly when you’re chasing only seven franchised buyers. Scale wins here, unequivocally.

Timing reinforces that scale. AmerisourceBergen’s FDD is current (2026), while ACASA’s is marked DUE, meaning AmerisourceBergen is actively recruiting franchisees and refreshing disclosures — a clear signal that the system is in expansion mode and ready to evaluate vendor partnerships right now. The same procurement model (approved_supplier) applies to both, so the selling effort is comparable: you’ll need to win a spot on a preferred list and prove ROI per unit. But with AmerisourceBergen, a successful pilot opens a network of over two thousand follow-on deals, whereas ACASA’s fast 40% unit growth still adds only a handful of new doors per year. The meaningful tradeoff is per-unit budget potential versus total network budget — and with AmerisourceBergen’s investment range stretching to $504K, the higher end of its franchisees can match or exceed ACASA’s spend comfort.

Verdict: AmerisourceBergen Drug delivers a massive, ready-to-buy TAM that turns software sales into a land-grab; ACASA’s high AUV is a rounding error against that scale.